The likelihood of rejecting the null hypothesis for the effect on ventilator-free days was 92 percent, with the assumption of a difference of 2.25 days and a typical deviation of 10.5 days. The data and safety monitoring board conducted an interim analysis after enrollment of the original 105 patients and after approximately every 250 patients enrolled. Sequential stopping rules for efficacy and futility, in addition to additional information on the scholarly study methods, are described in the scholarly study protocol. Only the website pharmacist, pharmacokinetic assay laboratory, coleaders of the coordinating center, and safety and data monitoring plank were alert to the study-group assignments. Results Baseline Characteristics of the Patients The first patient was enrolled on March 18, 2010, on September 30 and the info and safety monitoring board stopped the study because of futility, 2013, after enrollment of 745 patients .The rate of periprocedural myocardial infarction was lower in both groups, which may be a consequence of the approach used our trial to identify such events. The protocol mandated at least one biomarker determination throughout a right time screen of 18 to a day after PCI, or before discharge if this occurred earlier. We may have underestimated the rate of periprocedural myocardial infarction as a result, although this limitation pertains to both treatment groups given the blinding of the trial equally.22 The rate of stent thrombosis didn’t differ significantly between the two groups, and over fifty % the stent thromboses in both groups occurred through the first 30 days, when patients were prescribed dual antiplatelet therapy.